EMFRET presents the anti-GPVI lead candidate EMA601 in Late-Breakthrough Plenary Session at the ISTH Congress 2024 in Bangkok: compelling preclinical data in thrombosis and stroke.
Eibelstadt/Würzburg/Bangkok – 22 June 2024
EMFRET Analytics presented for the first time its humanized anti-platelet glycoprotein VI (GPVI) Fab fragment EMA601 in the Plenary Late-Breakthrough Session at the ISTH 2024 Congress in Bangkok, Thailand. The work, performed in collaboration with researchers from Julius-Maximilians-Universität Würzburg (JMU) and University Hospital Würzburg, highlighted the strong efficacy of EMA601 in preclinical models of arterial thrombosis and ischemic stroke.
EMA601 demonstrated potent inhibition of platelet-driven thrombus formation while preserving physiological hemostasis. In experimental stroke models, treatment with EMA601 markedly reduced thrombotic vessel occlusion and protected from ischemic brain injury, supporting the concept of selectively targeting GPVI to prevent pathological thrombosis without increasing bleeding risk.
The presentation drew considerable attention during the Late-Breakthrough Session, reflecting the growing interest in GPVI-targeted strategies for cardiovascular disease. The results further position EMA601 as a promising lead candidate for clinical development aimed at preventing thrombotic and thrombo-inflammatory complications such as stroke and myocardial infarction.
